Selank – Comprehensive Research Overview (2026)
Selank is a synthetic heptapeptide analog of tuftsin (Thr-Lys-Pro-Arg) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is approved in Russia for the treatment of anxiety and neurasthenia. Selank is primarily researched for its anxiolytic, nootropic, and mild immunomodulatory properties. Unlike benzodiazepines, it does not cause sedation, dependence, or withdrawal, making it a compelling research tool for anxiety and cognitive function.
→ View Selank (for laboratory research use only)
Chemical Structure and Properties
- Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (tuftsin + Pro-Gly-Pro stabilizing extension)
- Molecular Weight: ≈751 Da
- Form: Lyophilized powder or nasal spray solution
- Key Feature: Stabilized tuftsin analog with enhanced CNS penetration and prolonged activity
Mechanism of Action
- Modulates GABA-A receptor activity (anxiolytic effect without direct agonism).
- Increases expression of BDNF and serotonin in the hippocampus and prefrontal cortex.
- Regulates enkephalin metabolism, prolonging endogenous opioid activity.
- Mild immunomodulatory effects via tuftsin-like activity on macrophages and NK cells.
- Reduces stress-induced cortisol elevation without sedation.
Clinical Evidence and Research Findings
Multiple Russian clinical trials demonstrate efficacy for generalized anxiety disorder and neurasthenia, with a favorable tolerability profile. Selank is approved and widely used in Russia as a nasal spray. Western research is more limited but growing, with interest in its nootropic and stress-resilience properties. No large Western Phase 3 trials exist.
→ Interested in researching Selank? View Product Options
Benefits (Research & Clinical Observations)
- Anxiolytic effects without sedation or dependence
- Improved cognitive function, focus, and memory
- Stress resilience and reduced cortisol response
- Mild immunomodulatory support
- Potential antidepressant effects via BDNF upregulation
Typical Dosing Protocols (Off-Label / Research)
- Nasal spray: 250–750 μg per nostril, 2–3 times daily (approved Russian protocol)
- Subcutaneous: 250–500 μg once or twice daily
- Cycles: 2–4 weeks on, with breaks; or as needed for acute stress
Safety Profile and Side Effects
Selank has an excellent safety profile with decades of use in Russia. Common side effects: mild nasal irritation (spray), transient fatigue. No dependence, withdrawal, or significant sedation reported.
Selank vs Semax vs Diazepam – Quick Comparison
| Aspect | Selank | Semax | Diazepam |
|---|---|---|---|
| Primary Effect | Anxiolytic + nootropic | Nootropic + neuroprotective | Anxiolytic + sedative |
| Sedation | None | None | Yes |
| Dependence Risk | None reported | None reported | High |
| Approval Status | Approved (Russia) | Approved (Russia) | Approved (US/EU) |
Summary
Selank is a well-characterized anxiolytic and nootropic peptide with regulatory approval in Russia and a strong safety record. Its non-sedating, non-addictive profile makes it a valuable research tool for anxiety, stress resilience, and cognitive function. As with all compounds in this library, Selank is not FDA-approved and should only be considered under qualified medical supervision.
For Laboratory Research Use View Selank →
Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.